{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T18:44:43Z","timestamp":1758393883783,"version":"3.37.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1245\/s10434-024-15111-4","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T20:02:45Z","timestamp":1709150565000},"page":"3672-3674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["SOUND (Sentinel Node Versus Observation After Axillary Ultrasound) Trial: Are We Ready to Change the Tune of Our Breast Cancer Practice?"],"prefix":"10.1245","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8005-1072","authenticated-orcid":false,"given":"James W.","family":"Jakub","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Advani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Vallow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santo","family":"Maimone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"issue":"11","key":"15111_CR1","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jamaoncol.2023.3759","volume":"9","author":"OD Gentilini","year":"2023","unstructured":"Gentilini OD, Botteri E, Sangalli C, Galimberti V, et al. Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial. JAMA Oncol. 2023;9(11):1557\u201364. https:\/\/doi.org\/10.1001\/jamaoncol.2023.3759.","journal-title":"JAMA Oncol."},{"key":"15111_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:13.","journal-title":"Lancet Oncol."},{"issue":"3","key":"15111_CR3","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/SLA.0b013e3181f08f32","volume":"252","author":"AE Giuliano","year":"2010","unstructured":"Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of surgeons oncology group Z0011 randomized trial. Ann Surg. 2010;252(3):426\u201332. https:\/\/doi.org\/10.1097\/SLA.0b013e3181f08f32.","journal-title":"Ann Surg."},{"issue":"25","key":"15111_CR4","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Barlow WE, Gralow JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2108873.","journal-title":"N Engl J Med."},{"issue":"1","key":"15111_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, Toi M, O\u2019Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(1):77.","journal-title":"Lancet Oncol."},{"key":"15111_CR6","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-14835-z","author":"T Higgins","year":"2023","unstructured":"Higgins T, Kantor O, Harrison B, et al. Defining the biology of estrogen receptor-low-positive breast cancer. Ann Surg Oncol. 2023. https:\/\/doi.org\/10.1245\/s10434-023-14835-z.","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"15111_CR7","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/bjs.10791","volume":"105","author":"E Morrow","year":"2018","unstructured":"Morrow E, Lannigan A, Doughty J, et al. Population-based study of the sensitivity of axillary ultrasound imaging in the preoperative staging of node-positive invasive lobular carcinoma of the breast. Br J Surg. 2018;105(8):987\u201395. https:\/\/doi.org\/10.1002\/bjs.10791.","journal-title":"Br J Surg."},{"issue":"19","key":"15111_CR8","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1200\/JCO.2012.45.2615","volume":"31","author":"KS Hughes","year":"2013","unstructured":"Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382\u20137. https:\/\/doi.org\/10.1200\/JCO.2012.45.2615.","journal-title":"J Clin Oncol."},{"issue":"3","key":"15111_CR9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S1470-2045(14)71221-5","volume":"16","author":"IH Kunkler","year":"2015","unstructured":"Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM. PRIME II investigators Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIMEII): a randomised controlled trial. Lancet Oncol. 2015;16(3):266\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(14)71221-5.","journal-title":"Lancet Oncol."},{"issue":"5","key":"15111_CR10","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jamcollsurg.2019.01.022","volume":"228","author":"T Almerey","year":"2019","unstructured":"Almerey T, Villacreses D, Li Z, et al. Value of axillary ultrasound after negative axillary mri for evaluating nodal status in high-risk breast cancer. J Am Coll Surg. 2019;228(5):792\u20137. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2019.01.022.","journal-title":"J Am Coll Surg."},{"key":"15111_CR11","unstructured":"https:\/\/www.breastsurgeons.org\/news\/?id=100"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15111-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-15111-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15111-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T13:06:22Z","timestamp":1715087182000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-15111-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["15111"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-15111-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"type":"print","value":"1068-9265"},{"type":"electronic","value":"1534-4681"}],"subject":[],"published":{"date-parts":[[2024,2,28]]},"assertion":[{"value":"25 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.W.J. is on the advisory board of Breathe Biomedical, and Clarix has a royalty-bearing license agreement with Mayo Clinic and J.W.J and R.M. PA is on the advisory board for Breathe Biomedical, has received research funding (institution) from Genentech, Gilead, Agendia, AstraZeneca, Caris Life Sciences, Seagen, Atossa therapeutics, Modulation therapeutics, Sermonix, and Loxo Lilly; serves on the advisory board of Puma Biotechnologies, Epic Sciences, Biovica International, AstraZeneca, and Elephas; and does consulting and speakers bureau work for GE Healthcare, AstraZeneca, MJH Lifesciences, Menarini Stemline, and Iksuda Therapeutics; R.M is involved in mammogram CAD\/AI development for Imago Systems; L.V., S. Maimone, and S. McLaughlin have no disclosures to report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"DISCLOSURE"}}]}}